Rhythm Pharmaceuticals (RYTM) P/S ratio

P/S ratio today
39.9×

Rhythm Pharmaceuticals (RYTM) trades at 39.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 36.7×. That is 39.7% higher than the 26.2× of fiscal 2024. Figures as of 18 Nov 2026, 02:34 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
39.9×
P/S ratio, fiscal 2025
36.7×
Change on fiscal 2024
+39.7%
Highest on record
156.9×fiscal 2021
Lowest on record
26.2×fiscal 2024
Fiscal years on record
52021–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Rhythm Pharmaceuticals P/S ratio, in more detail

Today's figure is 8.9% above the fiscal 2025 year-end.

Across the 5 fiscal year-ends on record (2021–2025), the highest was 156.9× in fiscal 2021 and the lowest 26.2× in fiscal 2024. Today's P/S ratio is higher than at 60% of the 5 fiscal year-ends on record; their median is 36.7×.

History · 5 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Rhythm Pharmaceuticals P/S ratio, year by year

Rhythm Pharmaceuticals (RYTM) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today39.9×—$116.61—
202536.7× 39.7% up$107.04$2.92
202426.2× 23.4% down$55.98$2.13
202334.2× 46.7% down$45.97$1.34
202264.2× 59.1% down$29.12$0.45
2021156.9×—$9.98$0.06
2020——$29.73—
2019——$22.96—
2018——$26.88—
2017——$29.06—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

P/S ratio at health care companies of similar size

P/S ratio of Rhythm Pharmaceuticals and comparable companies
CompanyP/S ratio
Rhythm Pharmaceuticals RYTM42.6×
Alkermes ALKS5.2×
PACS Group PACS1.5×
Kiniksa Pharmaceuticals International KNSA11.0×
ImmunityBio IBRX58.8×
Cytokinetics CYTK81.7×

Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.

More on RYTM

Rhythm Pharmaceuticals, figure by figure

Rhythm Pharmaceuticals (RYTM) overview: price, valuation and scorecardAll health care companies by market value

Rhythm Pharmaceuticals P/S ratio: questions and answers

What is Rhythm Pharmaceuticals's P/S ratio?

Rhythm Pharmaceuticals (RYTM) trades at 39.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 36.7×. That is 39.7% higher than the 26.2× of fiscal 2024.

Is Rhythm Pharmaceuticals's P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 60% of the 5 fiscal year-ends on record; their median is 36.7×.

What are the highest and lowest P/S ratio figures on record for Rhythm Pharmaceuticals?

Across the 5 fiscal year-ends on record (2021–2025), the highest was 156.9× in fiscal 2021 and the lowest 26.2× in fiscal 2024.

How is Rhythm Pharmaceuticals's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Rhythm Pharmaceuticals (RYTM) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/RYTM/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.